Active substance

Results for the substance garadacimab

1 result

About this active substance

Garadacimab is a monoclonal antibody used to prevent attacks of hereditary angioedema in eligible patients. The disease causes episodes of painful swelling of the skin, digestive tract or airways. Garadacimab blocks factor XIIa, a component of the contact system, reducing activation of the cascade that leads to attacks.

It is given by subcutaneous injection according to the schedule set by the doctor. It is a preventive treatment, meaning it is used regularly to reduce attacks, not to rapidly treat an attack that has already started. Patients should still have an emergency plan and on-demand medicines, especially for throat swelling or breathing difficulty.

Side effects may include redness, pain, itching or bruising at the injection site, abdominal pain, blocked or runny nose, sore throat or cold-like symptoms. Like any biological medicine, it may cause hypersensitivity reactions. Not all long-term risks are known, and the doctor may monitor effectiveness and possible adverse reactions.

Seek urgent medical help if swelling of the tongue or throat, breathing difficulty, faintness, widespread hives, severe abdominal pain or rapid worsening of symptoms occurs. Tell the doctor if you are pregnant, breastfeeding, have infections, important allergies or a planned procedure. Regular administration is essential for prevention.